Report: Sleep and oxygen therapy trends show mixed outlook for growth

NEW YORK – Respondents saw improved sleep patient volume growth in the last 12 months, but they expect slower growth in the next 12 months, according to the 3Q25 HME Sleep and Oxygen Survey from Needham. 

Respondents saw their sleep patient volume increase by an average of 8.8% in the last 12 months (vs. 3.4% in the prior survey) and expect it to increase by 6.6% in the next 12 months (vs. 7.2% in the prior survey). 

Other highlights from the survey: 

Respondents are seeing a small loss of sleep patients from GLP-1 drugs. While 80% of respondents indicated they were unsure how many of their sleep patients were on GLP-1 drugs, the remaining 20% estimated that an average of 6.2% of their patients were on the drug. Of their overall sleep patients, respondents reported that 2.1% had stopped using CPAP therapy. 

Resmed looks likely to lose flow generator and mask market share over the next 12 months, despite having the highest rated flow generators and masks. Respondents expect Resmed's share of flow generator purchases to decrease 9.3% from 79.3% to 70% and its share of their mask purchases to decrease by 2.7% from 50.2% to 47.5% over the next 12 months. 

Respondents were also asked how their flow generator mix would change if Philips Respironics relaunched its flow generators with unlimited supply. Respondents indicated that their average flow generator mix would be 49.6% Resmed, followed by Philips Respironics at 25%, React Health at 16.5%, and other companies at 8.9%. 

Resmed had the highest-rated flow generators, nasal masks, nasal pillow masks and full-face masks. 

Flow generated prices saw the first decline in many years, while mask price increases improved slightly. Respondents reported that flow generator prices decreased by 0.4% in the last 12 months (vs. 0.9% increase in the prior survey). They reported that mask prices increased by 3% (vs. 2.9% in the prior survey). 

For home oxygen therapy: 

• Respondents saw their oxygen patient volume increase by an average of 1.6% in the past 12 months (vs. 1.3% in the prior survey) and expect it to increase by 3.3% in the next 12 months (vs. 5.6% in the prior survey). 
• Respondents expect Inogen and OxyGo’s combined share of portable oxygen concentrator (POC) purchases to decrease by 2.5% from 43.6% to 41.1%. Rhythm Healthcare had the highest rated POCs, followed by OxyGo and Inogen. 

The report was based on 16 completed surveys.